1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Highlights

Key Questions Answered

- The ME market has been dominated by anti-VEGF drugs Lucentis and Avastin for many years, however, rival drug Eylea has recently gained approval for ME indications across the 7MM. How will this impact the positions that Lucentis and Avastin hold in this market? How will this change over the forecast period, and which drug will covet the leading position in 2023?
- The current late stage AMD pipeline is varied, with first-in-class drugs in development for both dry AMD and wet AMD. Which of these will have the biggest impact on the AMD market? What strategies are developers undertaking to penetrate the wet AMD market? Will the novel dry AMD drugs fulfil the huge unmet need for this retinal disease?
- Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of age-related diseases such as AMD and conditions causing ME. How will epidemiological changes impact the growth of the future ME and AMD markets?

Key Findings

- The main driver of growth in the AMD market will be the introduction of first-in-class drugs over the forecast period. The launch of two new therapies for dry AMD will significantly grow this market and the arrival of adjunctive therapies for wet AMD will further strengthen this growth in the AMD market.
- The rapid expansion of Eylea within the ME market will lead to a shift in market leader over the forecast period, with Lucentis losing this position to rival anti-VEGF drug Eylea.
- The biggest barrier for growth in the ME and AMD markets will be the increasing pressure to show drug cost-effectiveness. This is likely to have a negative impact on these markets, as regulatory bodies are adopting stricter criteria for new drug approvals and reimbursement listing.
- Significant opportunities remain for further drug development in both the ME and AMD markets as numerous unmet needs remain, in particular the need for effective dry AMD drugs with non-invasive formulations.

Scope

- Overview of ME and AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized ME and AMD market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ME and AMD therapeutics markets.
- Pipeline analysis: focus on the seven late-stage pipeline ME and AMD drugs discussing emerging trends as well as overview of earlier phase drugs.
- Analysis of the current and future market competition in the global ME and AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global ME and AMD therapeutics markets.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ME and AMD therapeutics markets in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ME and AMD therapeutics markets from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 27
2.1 Related Reports 28
3 Disease Overview 29
3.1 Macular Degeneration Overview 29
3.1.1 Etiology and Pathophysiology 31
3.1.2 Classification 35
3.1.3 Symptoms and Diagnosis 37
3.2 Macular Edema Overview 40
3.2.1 Etiology and Pathophysiology 41
3.2.2 Classification 44
3.2.3 Symptoms and Diagnosis 45
4 Epidemiology - Macular Edema 48
4.1 Disease Background 48
4.2 Risk Factors and Comorbidities 48
4.3 Global Trends 49
4.3.1 US 50
4.3.2 5EU 50
4.3.3 Japan 51
4.4 Forecast Methodology 51
4.4.1 Sources Used 52
4.4.2 Sources Not Used 54
4.4.3 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 55
4.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetic Retinopathy 59
4.4.5 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 60
4.4.6 Forecast Assumptions and Methods - Total Prevalent Cases of ME following BRVO and CRVO 61
4.5 Epidemiological Forecast for Macular Edema (2013-2023) 62
4.5.1 Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 62
4.5.2 Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 64
4.5.3 Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population 66
4.5.4 Total Prevalent Cases of ME Following BRVO 68
4.5.5 Age-Specific Total Prevalent Cases of ME Following BRVO 70
4.5.6 Sex-Specific Total Prevalent Cases of ME following BRVO 72
4.5.7 Total Prevalent Cases of ME Following CRVO 74
4.5.8 Age-Specific Total Prevalent Cases of ME Following CRVO 76
4.5.9 Sex-Specific Total Prevalent Cases of ME Following CRVO 78
4.6 Discussion 80
4.6.1 Epidemiological Forecast Insight 80
4.6.2 Limitations of the Analysis 81
4.6.3 Strengths of the Analysis 82
5 Epidemiology - Age-Related Macular Degeneration 83
5.1 Disease Background 83
5.2 Risk Factors and Comorbidities 84
5.3 Global Trends 85
5.3.1 US 85
5.3.2 5EU 86
5.3.3 Japan 86
5.4 Forecast Methodology 87
5.4.1 Sources Used 88
5.4.2 Forecast Assumptions and Methods 90
5.5 Epidemiological Forecast for AMD (2013-2023) 94
5.5.1 Total Prevalent Cases of AMD 94
5.5.2 Age-Specific Total Prevalent Cases of AMD 95
5.5.3 Sex-Specific Total Prevalent Cases of AMD 97
5.5.4 Age-Standardized Total Prevalence of AMD 99
5.5.5 Total Prevalent Cases of AMD by Stage 101
5.5.6 Total Prevalent Cases of Late AMD by Subtype 102
5.6 Discussion 104
5.6.1 Epidemiological Forecast Insight 104
5.6.2 Limitations of the Analysis 105
5.6.3 Strengths of the Analysis 106
6 Disease Management 107
6.1 Diagnosis and Treatment Overview 107
6.1.1 Macular Edema Diagnosis 107
6.1.2 Macular Degeneration Diagnosis 107
6.1.3 Treatment Guidelines and Leading Prescribed Drugs 108
6.1.4 Clinical Practice 110
6.2 US 123
6.3 France 127
6.4 Germany 130
6.5 Italy 133
6.6 Spain 136
6.7 UK 139
6.8 Japan 142
7 Competitive Assessment 145
7.1 Overview 145
7.2 Product Profiles - Major Brands 146
7.2.1 Lucentis (ranibizumab) 146
7.2.2 Eylea (aflibercept) 157
7.2.3 Avastin (bevacizumab) 168
7.2.4 Macugen (pegaptanib sodium) 175
7.2.5 Visudyne (verteporfin) 178
7.2.6 Corticosteroid Implants 183
8 Unmet Need and Opportunity 195
8.1 Overview 195
8.2 Treatment for Dry AMD 196
8.2.1 Unmet Need 196
8.2.2 Gap Analysis 198
8.2.3 Opportunity 200
8.3 Longer-Acting Anti-VEGF Drug Therapy 202
8.3.1 Unmet Need 202
8.3.2 Gap Analysis 204
8.3.3 Opportunity 204
8.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 205
8.4.1 Unmet Need 205
8.4.2 Gap Analysis 206
8.4.3 Opportunity 207
8.5 Less Invasive Drug Formulations 207
8.5.1 Unmet Need 207
8.5.2 Gap Analysis 208
8.5.3 Opportunity 209
8.6 Awareness and Earlier Patient Diagnosis 210
8.6.1 Unmet Need 210
8.6.2 Gap Analysis 211
8.6.3 Opportunity 211
8.7 Home Monitoring of AMD Progression 212
8.7.1 Unmet Need 212
8.7.2 Gap Analysis 213
8.7.3 Opportunity 214
9 Pipeline Assessment 216
9.1 Overview 216
9.2 Clinical Trial Mapping 217
9.3 Promising Drugs in Clinical Development 218
9.3.1 Abicipar pegol 220
9.3.2 Fovista 227
9.3.3 Squalamine 235
9.3.4 Lampalizumab 243
9.3.5 Emixustat 250
9.3.6 Optina 257
9.3.7 DE-102 265
9.4 Promising Drugs in Early-Stage Development 269
9.4.1 Complement Inhibitors 269
9.5 Other Drugs in Development 271
9.6 Biosimilars 273
10 Current and Future Players 275
10.1 Overview 275
10.2 Trends in Corporate Strategy 277
10.3 Company Profiles 278
10.3.1 Roche/Genentech 278
10.3.2 Novartis 282
10.3.3 Regeneron 285
10.3.4 Bayer 289
10.3.5 Valeant 293
10.3.6 Allergan 296
10.3.7 Alimera Sciences 299
10.3.8 Ampio Pharmaceuticals 303
10.3.9 Ophthotech 305
10.3.10 Acucela 309
10.3.11 Ohr Pharmaceuticals 313
11 Market Outlook 316
11.1 Global Markets 316
11.1.1 Forecast 316
11.1.2 Drivers and Barriers - Global Issues 324
11.2 US 327
11.2.1 Forecast 327
11.2.2 Key Events 333
11.2.3 Drivers and Barriers 333
11.3 France 335
11.3.1 Forecast 335
11.3.2 Key Events 341
11.3.3 Drivers and Barriers 341
11.4 Germany 345
11.4.1 Forecast 345
11.4.2 Key Events 350
11.4.3 Drivers and Barriers 350
11.5 Italy 353
11.5.1 Forecast 353
11.5.2 Key Events 360
11.5.3 Drivers and Barriers 360
11.6 Spain 364
11.6.1 Forecast 364
11.6.2 Key Events 369
11.6.3 Drivers and Barriers 369
11.7 UK 372
11.7.1 Forecast 372
11.7.2 Key Events 378
11.7.3 Drivers and Barriers 378
11.8 Japan 382
11.8.1 Forecast 382
11.8.2 Key Events 388
11.8.3 Drivers and Barriers 388
12 Appendix 392
12.1 Bibliography 392
12.2 Abbreviations 427
12.3 Methodology 434
12.4 Forecasting Methodology 434
12.4.1 Diagnosed ME and AMD Patients 434
12.4.2 Percentage of Drug-Treated Patients 435
12.4.3 Drugs Included in Each Therapeutic Class 435
12.4.4 Launch and Patent Expiry Dates 435
12.4.5 General Pricing Assumptions 436
12.4.6 Individual Drug Assumptions 437
12.4.7 Pricing of Pipeline Agents 442
12.5 Primary Research - KOLs Interviewed for this Report 443
12.6 Primary Research - High-Prescribers Survey 444
12.7 About the Authors 445
12.7.1 Analyst 445
12.7.2 Therapy Area Director 445
12.7.3 Epidemiologist 446
12.7.4 Global Head of Healthcare 446
12.8 About GlobalData 447
12.9 Disclaimer 447

1.1 List of Tables

Table 1: ARM System Classification of AMD 36
Table 2: Symptoms of AMD 37
Table 3: Risk Factors for DME 49
Table 4: Comorbidities for DME 49
Table 5: 7MM, Sources of Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population 52
Table 6: 7MM, Sources of Total Prevalence of ME following BRVO and CRVO 52
Table 7: 7MM, Sources Not Used in Epidemiological Analysis of DME 55
Table 8: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ?20 Years, Both Sexes, N, 2013-2023 63
Table 9: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, (Row %), 2013 65
Table 10: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ?20 Years, N (Row %), 2013 67
Table 11: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 69
Table 12: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, (Row %), 2013 71
Table 13: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ?20 Years, N (Row %), 2013 73
Table 14: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 75
Table 15: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, (Row %), 2013 77
Table 16: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ?20 Years, N (Row %), 2013 79
Table 17: Risk Factors and Comorbidities for AMD 84
Table 18: Diagnostic Criteria for AMD 87
Table 19: 7MM, Sources of AMD Prevalence Data 88
Table 20: 7MM, Total Prevalent Cases of AMD, Ages ?50 Years, Both Sexes, N, 2013-2023 94
Table 21: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013 96
Table 22: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ?50 Years, N (Row %), 2013 98
Table 23: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ?50 Years, N (Row %), 2013 101
Table 24: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ?50 Years, N (Row %), 2013 103
Table 25: National and International Treatment Guidelines for ME and AMD 109
Table 26: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 110
Table 27: ME and AMD Disease Management - US 126
Table 28: ME and AMD Disease Management - France 129
Table 29: ME and AMD Disease Management - Germany 132
Table 30: ME and AMD Disease Management - Italy 135
Table 31: ME and AMD Disease Management - Spain 138
Table 32: ME and AMD Disease Management - UK 141
Table 33: ME and AMD Disease Management - Japan 144
Table 34: Leading Treatments for ME and AMD, 2014 146
Table 35: Product Profile - Lucentis 151
Table 36: Lucentis SWOT Analysis, 2014 156
Table 37: Global Sales Forecast ($m) for Lucentis, 2013-2023 157
Table 38: Approval Dates for Eylea 161
Table 39: Product Profile - Eylea 162
Table 40: Eylea — Common Adverse Reactions 166
Table 41: Eylea SWOT Analysis, 2014 167
Table 42: Global Sales Forecast ($m) for Eylea, 2013-2023 168
Table 43: Product Profile - Avastin 171
Table 44: Avastin SWOT Analysis, 2014 174
Table 45: Global Sales Forecast ($m) for Avastin, 2013-2023 175
Table 46: Product Profile - Macugen 177
Table 47: Product Profile - Visudyne 180
Table 48: Visudyne SWOT Analysis, 2014 182
Table 49: Global Sales Forecast ($m) for Visudyne, 2013-2023 183
Table 50: Product Profile - Ozurdex 186
Table 51: Product Profile - Iluvien 190
Table 52: Corticosteroid IVT Implants SWOT Analysis, 2014 193
Table 53: Global Sales Forecast ($m) for Ozurdex, 2013-2023 194
Table 54: Global Sales Forecast ($m) for Iluvien, 2013-2023 194
Table 55: Unmet Needs and Opportunities in ME and AMD 196
Table 56: Promising Drugs in Clinical Development for ME and AMD 219
Table 57: Comparison of Drugs in Development for ME and AMD, 2014 219
Table 58: Product Profile - Abicipar pegol 222
Table 59: SWOT Analysis - Abicipar pegol, 2014 226
Table 60: Global Sales Forecast ($m) for Abicipar Pegol, 2013-2023 227
Table 61: Product Profile - Fovista 231
Table 62: SWOT Analysis - Fovista, 2014 234
Table 63: Global Sales Forecast ($m) for Fovista, 2013-2023 235
Table 64: Product Profile - Squalamine 238
Table 65: SWOT Analysis - Squalamine, 2014 242
Table 66: Global Sales Forecast ($m) for squalamine, 2013-2023 243
Table 67: Product Profile - Lampalizumab 246
Table 68: SWOT Analysis - Lampalizumab, 2014 249
Table 69: Global Sales Forecast ($m) for lampalizumab, 2013-2023 250
Table 70: Product Profile - Emixustat 253
Table 71: SWOT Analysis - Emixustat, 2014 256
Table 72: Global Sales Forecast ($m) for emixustat, 2013-2023 257
Table 73: Product Profile - Optina 259
Table 74: SWOT Analysis - Optina, 2014 263
Table 75: Global Sales Forecast ($m) for Optina, 2013-2023 264
Table 76: Product Profile - DE-102 266
Table 77: DE-102 SWOT Analysis, 2014 268
Table 78: Global Sales Forecast ($m) for DE-102, 2013-2023 269
Table 79: Early-Stage Drugs in Clinical Development for ME and AMD, 2014 272
Table 80: Key Companies in the ME and AMD Markets in the 7MM, 2014 275
Table 81: Roche/Genentech's ME and AMD Portfolio Assessment, 2014 281
Table 82: Novartis' ME and AMD Portfolio Assessment, 2014 284
Table 83: Regeneron's ME and AMD Portfolio Assessment, 2014 288
Table 84: Bayer's ME and AMD Portfolio Assessment, 2014 292
Table 85: Valeant's AMD Portfolio Assessment, 2014 295
Table 86: Allergan's ME and AMD Portfolio Assessment, 2014 298
Table 87: Alimera Sciences' ME Portfolio Assessment, 2014 301
Table 88: Ampio's ME Portfolio Assessment, 2014 304
Table 89: Ophthotech's AMD Portfolio Assessment, 2014 308
Table 90: Acucela's AMD Portfolio Assessment, 2014 312
Table 91: Ohr Pharmaceutical's AMD Portfolio Assessment, 2014 315
Table 92: Global Sales Forecast ($m) for ME, 2013-2023 318
Table 93: Global Sales Forecast ($m) for AMD, 2013-2023 321
Table 94: ME and AMD Markets - Drivers and Barriers, 2013-2023 324
Table 95: Sales Forecast ($m) for ME in the U, 2013-2023 329
Table 96: Sales Forecast ($m) for AMD in the United States, 2013-2023 331
Table 97: Key Events Impacting Sales for ME and AMD in the US, 2013-2023 333
Table 98: ME and AMD Markets - Drivers and Barriers in the US, 2013-2023 333
Table 99: Sales Forecast ($m) for ME in France, 2013-2023 337
Table 100: Sales Forecast ($m) for AMD in France, 2013-2023 339
Table 101: Key Events Impacting Sales for ME and AMD in France, 2013-2023 341
Table 102: ME and AMD Markets - Drivers and Barriers in France, 2013-2023 341
Table 103: Sales Forecast ($m) for ME in Germany, 2013-2023 346
Table 104: Sales Forecast ($m) for AMD in Germany, 2013-2023 348
Table 105: Key Events Impacting Sales for ME and AMD in Germany, 2013-2023 350
Table 106: ME and AMD Markets - Drivers and Barriers in Germany, 2013-2023 350
Table 107: Sales Forecast ($m) for ME in Italy, 2013-2023 356
Table 108: Sales Forecast ($m) for AMD in Italy, 2013-2023 358
Table 109: Key Events Impacting Sales for MME and AMD in Italy, 2013-2023 360
Table 110: ME and AMD Markets - Drivers and Barriers in Italy, 2013-2023 360
Table 111: Sales Forecast ($m) for ME in Spain, 2013-2023 365
Table 112: Sales Forecast ($m) for AMD in Spain, 2013-2023 367
Table 113: Key Events Impacting Sales for ME and AMD in Spain, 2013-2023 369
Table 114: ME and AMD Markets - Drivers and Barriers in Spain, 2013-2023 369
Table 115: Sales Forecast ($m) for ME in the UK, 2013-2023 374
Table 116: Sales Forecast ($m) for AMD in the UK, 2013-2023 376
Table 117: Key Events Impacting Sales for ME and AMD in the UK, 2013-2023 378
Table 118: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023 378
Table 119: Sales Forecast ($m) for ME in Japan, 2013-2023 384
Table 120: Sales Forecast ($m) for AMD in Japan, 2013-2023 386
Table 121: Key Events Impacting Sales for ME and AMD in Japan, 2013-2023 388
Table 122: ME and AMD Markets - Drivers and Barriers in Japan, 2013-2023 388
Table 123: Key Launch Dates 435
Table 124: Key Patent Expiries 436
Table 125: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 444

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 29
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 38
Figure 3: Color Fundus Photographs of Dry and Wet AMD 38
Figure 4: FAF Imaging of GA 39
Figure 5: Imaging of wAMD 40
Figure 6: CMT in DME 46
Figure 7: RVOs (BRVO and CRVO) on an FA 47
Figure 8: Increased CRT in ME-RVO 47
Figure 9: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages ?20 Years, Both Sexes, N, 2013-2023 64
Figure 10: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, 2013 66
Figure 11: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages ?20 Years, N, 2013 68
Figure 12: 7MM, Total Prevalent Cases of ME Following BRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 70
Figure 13: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, 2013 72
Figure 14: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages ?20 Years, N, 2013 74
Figure 15: 7MM, Total Prevalent Cases of ME Following CRVO, Ages ?20 Years, Both Sexes, N, 2013-2023 76
Figure 16: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, 2013 78
Figure 17: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages ?20 Years, N, 2013 80
Figure 18: 7MM, Total Prevalent Cases of AMD, Ages ?50 Years, Both Sexes, N, 2013-2023 95
Figure 19: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013 97
Figure 20: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ?50 Years, N, 2013 99
Figure 21: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age ?50 Years, by Sex, 2013 100
Figure 22: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age ?50 Years, N, 2013 102
Figure 23: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age ?50 Years, N, 2013 104
Figure 24: ME Clinical Treatment Flowchart 116
Figure 25: AMD Clinical Treatment Flowchart 123
Figure 26: Eylea's Clinical Development in DME and ME-BRVO 162
Figure 27: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME 190
Figure 28: ME and AMD therapeutics - Number of Phase II and III Clinical Trials in Each Indication in the 7MM 218
Figure 29: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023 220
Figure 30: Abicipar Pegol's Clinical Development in wAMD and DME 223
Figure 31: Clinical and Commercial Positioning of abicipar pegol 225
Figure 32: Fovista's Clinical Development in wAMD 232
Figure 33: Clinical and Commercial Positioning of Fovista 233
Figure 34: Squalamine's Clinical Development in wAMD and DME 239
Figure 35: Clinical and Commercial Positioning of squalamine 241
Figure 36: Lampalizumab's Development in wAMD 246
Figure 37: Clinical and Commercial Positioning of lampalizumab 248
Figure 38: Emixustat Clinical Development in dAMD 253
Figure 39: Clinical and Commercial Positioning of emixustat 255
Figure 40: Optina's Clinical Development in DME 260
Figure 41: Clinical and Commercial Positioning of Optina 262
Figure 42: DE-102's Clinical Development in DME and ME-BRVO 266
Figure 43: Clinical and Commercial Positioning of DE-102 267
Figure 44: Global Sales of Branded Products for ME and AMD by Company, 2013-2023 276
Figure 45: Company Portfolio Gap Analysis in ME and AMD, 2013-2023 277
Figure 46: Roche/Genentech's SWOT Analysis in ME and AMD, 2013-2023 281
Figure 47: Novartis' SWOT Analysis in ME and AMD, 2013-2023 285
Figure 48: Regeneron's SWOT Analysis in ME and AMD, 2013-2023 289
Figure 49: Bayer's SWOT Analysis in ME and AMD, 2013-2023 292
Figure 50: Valeant's SWOT Analysis in AMD, 2013-2023 295
Figure 51: Allergan's SWOT Analysis in ME and AMD, 2013-2023 299
Figure 52: Alimera Sciences' SWOT Analysis in ME, 2013-2023 302
Figure 53: Ampio's SWOT Analysis in ME, 2013-2023 305
Figure 54: Ophthotech's SWOT Analysis in AMD, 2013-2023 309
Figure 55: Acucela's SWOT Analysis in AMD, 2013-2023 312
Figure 56: Ohr Pharmaceutical's SWOT Analysis in AMD, 2013-2023 315
Figure 57: Global Sales for ME by Region, 2013-2023 319
Figure 58: Individual Drug Sales for ME 2013-2023 320
Figure 59: Global Sales for AMD by Region, 2013-2023 322
Figure 60: Individual Drug Sales for AMD 2013-2023 323
Figure 61: Individual Drug Sales for ME in the US, 2013-2023 330
Figure 62: Individual Drug Sales for AMD in the US, 2013-2023 332
Figure 63: Individual Drug Sales for ME in France, 2013-2023 338
Figure 64: Individual Drug Sales for AMD in France, 2013-2023 340
Figure 65: Individual Drug Sales for ME in Germany, 2013-2023 347
Figure 66: Individual Drug Sales for AMD in Germany, 2013-2023 349
Figure 67: Individual Drug Sales for ME in Italy, 2013-2023 357
Figure 68: Individual Drug Sales for AMD in Italy, 2013-2023 359
Figure 69: Individual Drug Sales for ME in Spain, 2013-2023 366
Figure 70: Individual Drug Sales for AMD in Spain, 2013-2023 368
Figure 71: Individual Drug Sales for ME in the UK, 2013-2023 375
Figure 72: Individual Drug Sales for AMD in the UK, 2013-2023 377
Figure 73: Individual Drug Sales for ME in Japan, 2013-2023 385
Figure 74: Individual Drug Sales for AMD in Japan, 2013-2023 387

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Europe Market Report for Fundus Cameras 2017 - MedCore

Europe Market Report for Fundus Cameras 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Europe Market Report for Slit Lamps 2017 - MedCore

Europe Market Report for Slit Lamps 2017 - MedCore

  • $ 5995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.